<DOC>
	<DOC>NCT02791867</DOC>
	<brief_summary>The primary objective is to determine if subjects taking the natural product AphoelineBrake™ in addition to their standard treatment experience differences in metabolic disease control, gastrointestinal hormones and inflammatory markers diet, hunger, satiety, weight, compared to patients taking a placebo in addition to their standard treatment. The secondary objective is to study the effect of Aphoeline Brake on oxidative and inflammatory stress markers.</brief_summary>
	<brief_title>Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrake</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Age ≥21 years Diagnosis of T2DM Metformin as first line treatment HbA1c ≥7 Calculated HOMAIR ≥3.0, BMI 2545 Triglyceride level ≥ 2.26 mmol/L Age &lt;21 years of age BMI ≤ 25 Pregnant Subjects on chronic nonsteroidal antiinflammatory drugs or systemic corticosteroids. Subjects treated with Liraglutide (Victoza®). Renal, hepatic or cardiac failure. Subjects with a significant clinical illness within a month before the first administration of Aphoeline Brake™ Subjects diagnosed with Irritable Bowel Syndrome. Subjects diagnosed with Ulcerative Colitis or Crohn's disease. History of significant gastrointestinal disease. Poor venous access. Poor likelihood to adhere with study procedures, as documented during the MyFitnessPal procedures prior to use of Aphoeline Brake™</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>